Glutathione
HCC
The First Affiliated Hospital of Zhengzhou Universityprotein_peptidePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 81/ 100
Competitive context
26 Active assets in the HCC cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
EOB-DTPA Charite University, Berlin, Germany | Phase 4 | BB |
CARVEDILOL Tongji Hospital | Phase 4 | BB |
Hepcortespenlisimut-L Immunitor LLC | Phase 3 | B |
Tirelizumab Chen Xiaoping | Phase 4 | B |
ASCRINVACUMAB Suzhou Kintor Pharmaceutical Inc, | Phase 2 | B |
View all 39 →
Same molecule, other indications
Glutathione is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →